Rheumatoid arthritis
Conditions
Interventions
Sponsors
Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who fulfilled the 1990 ACR classification criteria for giant cell arteritis and Takayasu arteritis and the 2012 EULAR/ACR provisional classification criteria for PMR 1) Bloch DA, et al.: The ACR 1990 criteria for the classification of vasculitis. Patients and methods. Arthritis Rheum 1990; 33:1068-1073 2) Dasgupta B, et al.: 2012 Provisional classification criteria for polymyalgia rheumatica: a EULAR/ACR collaborative initiative. Arthritis Rheum 2012; 64: 943-954
Exclusion criteria
Exclusion criteria: 1) patients who are prohibited to use tocilizumab by the JCR guideline for proper tocilizumab use 2) patients who are thought to be inappropriate for the treatment with tocilizumab by their attending doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mprovement of major clinical signs and symptoms at week 12(fever,abnormal findings of temporal artery, myalgia, serum CRP, ESR, abnormal radiological findings of the affected vessels) | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of major clinical signs at week 52, relapse rate and adverse events during 52 weeks | — |
Countries
Japan
Contacts
Public ContactRyota Sakai
Saitama Medical Center, Saitama Medical Universitity Department of Rheumatology & Clinical Immunology
Outcome results
None listed